Having trouble accessing articles? Reset your cache.

Dual ESMO readouts could expand Lynparza's reach to new patients

In a pair of wins for Lynparza, new data presented at ESMO showed the PARP inhibitor led to survival benefits in both a biomarker-selected group of prostate cancer patients and a combination with Avastin to treat ovarian cancer in a first-line maintenance setting.

Lynparza is one of several

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE